A Global First-in-Human Study in NSCLC, HNSCC, and Solid Tumors With Azirkitug as a Single Agent and in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

This study is testing a new drug called azirkitug to see if it is safe and effective at treating various solid tumors, including lung, head, and neck cancers. Researchers want to know how the body reacts to this drug, both on its own and when combined with other existing cancer therapies.

This trial is for adults with specific types of advanced cancers who are able to perform daily activities. You must have measurable tumors, recent lab results that meet safety standards, and your cancer must have progressed despite previous standard treatments.

Participants will receive the study medication through an intravenous (IV) infusion at a clinic or hospital for up to two years. Throughout the study, you will have regular check-ups, blood tests, and scans to monitor your health and how your body responds to the treatment.

The study is currently recruiting patients at approximately 80 locations worldwide, including several sites in California. Please speak with your oncologist to see if a nearby location is right for you.